Abstract:ATP citrate lyase (ACLY), generating most of the nucleocytosolic acetyl coenzyme A (acetyl-CoA) for histone acetylation, links cell metabolism to epigenetic regulation. Recent investigations demonstrated that ACLY activated by metabolic reprogramming played an essential role in both M1 and M2 macrophage activation via histone acetylation, previous studies also revealed that histone methylation and acetylation were critical for transcriptional regulation of osteoclast-specific genes. Considering that osteoclast differentiation also undergoes metabolic reprogramming and the activity of ACLY is always Akt-dependent, we inferred that RANK activation might enhance the activity of ACLY through downstream pathways and ACLY might play a role in osteoclast formation. In the current study, we found that ACLY was gradually activated during RANKL-induced osteoclast differentiation from bone marrow-derived macrophages (BMMs), both ACLY knock-down and small molecular ACLY inhibitor BMS-303141 significantly decreased nucleocytosolic acetyl-CoA in BMMs and osteoclasts and suppressed osteoclast formation in vitro, BMS-303141 also suppressed osteoclast formation in vivo and prevents OVX-induced bone loss. Further investigations showed that RANKL triggered ACLY translocation into nucleus, consistent with the increasing histone H3 acetylation which was correlated to ACLY. The H3 lysine residues influenced by ACLY were in accordance with GCN5 targets, using GCN5 knock-down and overexpression we showed that ACLY and GCN5 functioned in the same pathway for histone H3 acetylation. Analysis of pathways downstream of RANK activation revealed that ACLY was Akt-dependent and predominately affected Akt pathway. With the help of RNA-sequencing, we discovered Rac1 as a downstream regulator of ACLY, which was involved in shACLY-mediated suppression of osteoclast differentiation, cytoskeleton organization and signal transduction and was transcriptionally regulated by ACLY via histone H3 acetylation. To summarize, our results proved that inhibition of ATP-citrate lyase led to suppression of osteoclast differentiation and function via regulation of histone acetylation, Rac1 could be a downstream regulator of ACLY.

Cortactin controls bone homeostasis through regulating the differentiation of osteoblasts and osteoclasts

C/Ebp Alpha Regulates Osteoclast Lineage Commitment

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

The Regulation of E3 Ubiquitin Ligases Cbl and its Cross-talking in Bone Homeostasis

Mtorc1 Inhibits NF-κB/NFATc1 Signaling and Prevents Osteoclast Precursor Differentiation, in Vitro and in Mice

Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.

Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG.

Inactivation of Regulatory-associated Protein of Mtor (raptor)/mammalian Target of Rapamycin Complex 1 (mtorc1) Signaling in Osteoclasts Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice.

Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways

STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription

Bone Size and Quality Regulation: Concerted Actions of mTOR in Mesenchymal Stromal Cells and Osteoclasts

The molecular understanding of osteoclast differentiation

mTORC1 Prevents Preosteoblast Differentiation through the Notch Signaling Pathway

Osteoclast Differentiation and Gene Regulation

Metastasis suppressor 1 controls osteoblast differentiation and bone homeostasis through regulating Src-Wnt/β-catenin signaling

MACF1 promotes osteoblast differentiation by sequestering repressors in cytoplasm

The stiffness and collagen control differentiation of osteoclasts with an altered expression of c-Src in podosome

Gs Alpha Controls Cortical Bone Quality By Regulating Osteoclast Differentiation Via Camp/Pka And Beta-Catenin Pathways

Microtubule Actin Crosslinking Factor 1 Promotes Osteoblast Differentiation by Promoting Β‐catenin/tcf1/runx2 Signaling Axis

C-C Chemokine Receptor Type 6 Modulates the Biological Function of Osteoblastogenesis by Altering the Expression Levels of Osterix and OPG/RANKL

Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation